Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,256,019 papers from all fields of science
Search
Sign In
Create Free Account
Stage 3 lower case b
Known as:
stage 3b
, stage iiib
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Stage 3B
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)
V. Franke
,
D. Berger
,
+6 authors
A. V. van Akkooi
International Journal of Cancer
2019
Corpus ID: 59340728
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in…
Expand
Review
2018
Review
2018
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer
E. Ko
,
D. Raben
,
S. Formenti
Clinical Cancer Research
2018
Corpus ID: 49428767
Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for stage I to stage IIIA disease, and are…
Expand
Highly Cited
2009
Highly Cited
2009
Vascularized iliac bone-grafting for osteonecrosis with segmental collapse of the femoral head.
Chun-Chieh Chen
,
Chun-Li Lin
,
Wei-Chih Chen
,
H. Shih
,
S. Ueng
,
Mel S. Lee
Journal of Bone and Joint Surgery. American…
2009
Corpus ID: 44863979
BACKGROUND Vascularized iliac bone-grafting has been reported to be successful for patients with osteonecrosis of the femoral…
Expand
2007
2007
Prognostic Factors Affecting Locoregional Recurrence in Patients with Stage IIIB Noninflammatory Breast Cancer
K. Gülben
,
U. Berberoǧlu
,
A. Cengiz
,
H. Altınyollar
World Journal of Surgery
2007
Corpus ID: 13180853
BackgroundThe aim of the present study was to identify the clinicopathological factors affecting locoregional recurrence (LRR) in…
Expand
Highly Cited
2004
Highly Cited
2004
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.
G. Somlo
,
P. Frankel
,
+16 authors
J. Doroshow
Journal of Clinical Oncology
2004
Corpus ID: 43203817
PURPOSE To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially…
Expand
Highly Cited
2004
Highly Cited
2004
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a…
J. Dancey
,
F. Shepherd
,
R. Gralla
,
Y. S. Kim
Lung Cancer
2004
Corpus ID: 23378958
Highly Cited
2002
Highly Cited
2002
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.
T. Buchholz
,
S. Tucker
,
+12 authors
G. Hortobagyi
Journal of Clinical Oncology
2002
Corpus ID: 22452026
PURPOSE To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant…
Expand
Highly Cited
1999
Highly Cited
1999
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
P. Comella
,
G. Frasci
,
+14 authors
G. Comella
Journal of Clinical Oncology
1999
Corpus ID: 31777064
PURPOSE In a previous phase I study cisplatin (CDDP), gemcitabine (GEM), and vinorelbine (VNR) combination therapy was safe and…
Expand
1998
1998
Possible role of glutathione in predicting radiotherapy response of cervix cancer.
G. K. Jadhav
,
P. Bhanumathi
,
+5 authors
J. Solomon
International Journal of Radiation Oncology…
1998
Corpus ID: 19126041
Highly Cited
1997
Highly Cited
1997
Prognostic value of pleural effusion in patients with non-small cell lung cancer.
S. Sugiura
,
Y. Ando
,
H. Minami
,
M. Ando
,
S. Sakai
,
K. Shimokata
Clinical Cancer Research
1997
Corpus ID: 10570586
This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC) has a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE